ARCHIVES

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

Clearinghouse Insists On New Dichlorvos Test; CSWG Disagrees

March 24, 1978

Five Year Survival Up To 48 Percent; DeVita Has “No Doubt” It Is Really Over 50 Percent Now

December 2, 1983

California approves $3 billion program for stem-cell research.

November 5, 2004

In Brief: Mark Kochevar Named New Administrative Officer Of DCE; Thomas Necheles Dies Suddenly at 51

September 21, 1984

NCAB Approves, NCI Accepts Powers’ Version Of Board’s Organ Systems Recommendations

May 27, 1983

Chart of Core Grants

October 18, 1991